128 related articles for article (PubMed ID: 37625937)
1. Predictive factors for acceptance of a long-acting opiate substitution treatment studied through social representations and internalized stigma.
Lacroix A; Puybaret V; Villéger P; Zattoni-Leroy J; Cantaloube S; Chevalier C; Nubukpo P
Therapie; 2024; 79(3):307-317. PubMed ID: 37625937
[TBL] [Abstract][Full Text] [Related]
2. Exploring the Concepts of Abstinence and Recovery Through the Experiences of Long-Term Opiate Substitution Clients.
Notley C; Blyth A; Maskrey V; Pinto H; Holland R
Subst Abus; 2015; 36(2):232-9. PubMed ID: 25127184
[TBL] [Abstract][Full Text] [Related]
3. A qualitative study of reasons for seeking and ceasing opioid substitution treatment in prisons in New South Wales, Australia.
Larney S; Zador D; Sindicich N; Dolan K
Drug Alcohol Rev; 2017 May; 36(3):305-310. PubMed ID: 27325289
[TBL] [Abstract][Full Text] [Related]
4. Barriers to accessing opioid substitution treatment for opioid use disorder: A systematic review from the client perspective.
Hall NY; Le L; Majmudar I; Mihalopoulos C
Drug Alcohol Depend; 2021 Apr; 221():108651. PubMed ID: 33667783
[TBL] [Abstract][Full Text] [Related]
5. Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities.
Johnson B; Richert T
Harm Reduct J; 2019 May; 16(1):31. PubMed ID: 31046774
[TBL] [Abstract][Full Text] [Related]
6. "Should I stay or should I go?" Coming off methadone and buprenorphine treatment.
Winstock AR; Lintzeris N; Lea T
Int J Drug Policy; 2011 Jan; 22(1):77-81. PubMed ID: 20956077
[TBL] [Abstract][Full Text] [Related]
7. Willingness to receive intravenous buprenorphine treatment in opioid-dependent people refractory to oral opioid maintenance treatment: results from a community-based survey in France.
Roux P; Rojas Castro D; Ndiaye K; Briand Madrid L; Laporte V; Mora M; Maradan G; Morel S; Spire B; Carrieri P
Subst Abuse Treat Prev Policy; 2017 Nov; 12(1):46. PubMed ID: 29096661
[TBL] [Abstract][Full Text] [Related]
8. Perceived healthcare stigma among patients in opioid substitution treatment: a qualitative study.
Garpenhag L; Dahlman D
Subst Abuse Treat Prev Policy; 2021 Oct; 16(1):81. PubMed ID: 34702338
[TBL] [Abstract][Full Text] [Related]
9. Factor structure, internal reliability and construct validity of the Methadone Maintenance Treatment Stigma Mechanisms Scale (MMT-SMS).
Smith LR; Mittal ML; Wagner K; Copenhaver MM; Cunningham CO; Earnshaw VA
Addiction; 2020 Feb; 115(2):354-367. PubMed ID: 31478272
[TBL] [Abstract][Full Text] [Related]
10. Supervised dosing with a long-acting opioid medication in the management of opioid dependence.
Saulle R; Vecchi S; Gowing L
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011983. PubMed ID: 28447766
[TBL] [Abstract][Full Text] [Related]
11. Stigma associated with medication treatment for young adults with opioid use disorder: a case series.
Hadland SE; Park TW; Bagley SM
Addict Sci Clin Pract; 2018 May; 13(1):15. PubMed ID: 29730987
[TBL] [Abstract][Full Text] [Related]
12. Memory function in opioid-dependent patients treated with methadone or buprenorphine along with benzodiazepine: longitudinal change in comparison to healthy individuals.
Rapeli P; Fabritius C; Kalska H; Alho H
Subst Abuse Treat Prev Policy; 2009 Apr; 4():6. PubMed ID: 19374740
[TBL] [Abstract][Full Text] [Related]
13. The effectiveness of different singly administered high doses of buprenorphine in reducing suicidal ideation in acutely depressed people with co-morbid opiate dependence: a randomized, double-blind, clinical trial.
Ahmadi J; Jahromi MS; Ehsaei Z
Trials; 2018 Aug; 19(1):462. PubMed ID: 30157924
[TBL] [Abstract][Full Text] [Related]
14. Underutilization of medications to treat opioid use disorder: What role does stigma play?
Allen B; Nolan ML; Paone D
Subst Abus; 2019; 40(4):459-465. PubMed ID: 31550201
[TBL] [Abstract][Full Text] [Related]
15. Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis.
Yarborough BJ; Stumbo SP; McCarty D; Mertens J; Weisner C; Green CA
Drug Alcohol Depend; 2016 Mar; 160():112-8. PubMed ID: 26796596
[TBL] [Abstract][Full Text] [Related]
16. The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom.
Hickman M; Steer C; Tilling K; Lim AG; Marsden J; Millar T; Strang J; Telfer M; Vickerman P; Macleod J
Addiction; 2018 Aug; 113(8):1461-1476. PubMed ID: 29672985
[TBL] [Abstract][Full Text] [Related]
17. A pilot feasibility randomised controlled trial of an adjunct brief social network intervention in opiate substitution treatment services.
Day E; Copello A; Seddon JL; Christie M; Bamber D; Powell C; Bennett C; Akhtar S; George S; Ball A; Frew E; Goranitis I; Freemantle N
BMC Psychiatry; 2018 Jan; 18(1):8. PubMed ID: 29334921
[TBL] [Abstract][Full Text] [Related]
18. [High-dose buprenorphine substitution during incarceration. Management of opiate addicts].
Revnaud-Maurupt C; Caer Y; Escaffre N; Gagneau M; Galinier A; Marzo JN; Meroueh F
Presse Med; 2005 Apr; 34(7):487-90. PubMed ID: 15902999
[TBL] [Abstract][Full Text] [Related]
19. Buprenorphine for managing opioid withdrawal.
Gowing L; Ali R; White JM; Mbewe D
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD002025. PubMed ID: 28220474
[TBL] [Abstract][Full Text] [Related]
20. Regaining control: the patient experience of supervised compared with unsupervised consumption in opiate substitution treatment.
Notley C; Holland R; Maskrey V; Nagar J; Kouimtsidis C
Drug Alcohol Rev; 2014 Jan; 33(1):64-70. PubMed ID: 24256157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
